Abstract 3293
Background
Empagliflozin (EMPA), a selective inhibitor of the sodium glucose co-transporter 2, reduces the risk of hospitalization for heart failure or cardiovascular death, as seen in the EMPA-REG OUTCOME trial.
Methods
We incubated EMPA alone or in combination with Doxorubicin in HL-1 adult cardiomyocytes evaluating: cell viability, lipid peroxidation, Leukotriene-B4 expression, NF-κB activation and Interleukin 1β, 8 and 6 secretion. To evaluate cardiac function in vivo, Global Longitudinal Strain (GLS) was measured using 2D speckle tracking echocardiography in C57BL6 mice treated with Doxorubicin (2.25 mg/kg/day ip) or EMPA (10 mg/kg/day) or EMPA and Doxorubicin in combination for 7 days. Cardiac lysates were processed for analysis of pro-inflammatory Interleukins.
Results
EMPA, co-incubated with Doxorubicin, enhanced significantly the viability of cardiomyocytes, compared to only Doxorubicin treated cells. EMPA reduces the lipid peroxidation during exposure to Doxorubicin. Moreover, EMPA has shown anti-inflammatory activity reducing both Leukotriene B4 and NF-kB expression. Notably, EMPA also decreased the expression of IL-1β, IL-6 and IL-8 of 40-50 % for all, compared to only Doxorubicin exposed cells. In preclinical models, after treatments only with Doxorubicin, GLS decreased significantly, while associating the pretreatment and subsequent combinatorial treatment with EMPA, we observed a prevention of the GLS’s reduction, indicating cardiprotective effects of the hypoglycemic drug. Moreover, we demonstrated that mice treated with EMPA and Doxorubicin the cardiac IL-1β, IL-6 and IL-8 were reduced of 45-60 % compared to mice treated only with Doxorubicin.
Conclusions
We demonstrated for the first time that EMPA exerts anti-oxidant and anti-inflammatory properties during incubation with Doxorubicin. Preclinical studies demonstrated cardioprotective effects of EMPA, with significant reductions of key mediators of cardiotoxicity. These results lay the biochemical and pathophysiological bases for subsequent preclinical and clinical studies concerning the use of EMPA as a cardioprotective agent during treatment with Doxorubicin.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
“Ricerca Corrente” grant from the Italian Ministry of Health.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
3611 - Phase II trial of SM 88 in Non-Metastatic Biochemical Recurrent Prostate Cancer.
Presenter: Benjamin Gartrell
Session: Poster Display session 3
Resources:
Abstract
2492 - A phase 1 study of Ad5 PSA/MUC-1/Brachyury Vaccine in Patients with Metastatic Castration Resistant Prostate Cancer (mCRPC)
Presenter: Marijo Bilusic
Session: Poster Display session 3
Resources:
Abstract
3142 - Multicenter Phase I Trial of a DNA Vaccine Encoding the Androgen Receptor Ligand Binding Domain (pTVG-AR, MVI-118) in Patients with Metastatic Prostate Cancer
Presenter: Douglas McNeel
Session: Poster Display session 3
Resources:
Abstract
4327 - Impact of germline mutations in Homologous Recombination (HR) genes on the response to Radium-223 for metastatic castration resistant prostate cancer (mCRPC)
Presenter: Elena Castro
Session: Poster Display session 3
Resources:
Abstract
3600 - Serum biomarkers of bone metabolism in metastatic castration-resistant prostate cancer (mCRPC) patients (pts) treated with Radium-223 (Ra223): Results from a prospective multicentre study
Presenter: Nuria Romero Laorden
Session: Poster Display session 3
Resources:
Abstract
3742 - Prognostic value of tumor suppression genes (TP53, PTEN, Rb) in metastatic hormone sensitive prostate cancer
Presenter: Miguel Gonzalez Velez
Session: Poster Display session 3
Resources:
Abstract
2643 - Germline sequencing of advanced prostate cancer patients in the BARCODE2 trial
Presenter: Sarah Benafif
Session: Poster Display session 3
Resources:
Abstract
4349 - Impact of treatment sequence in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC): data from the prospective PROREPAIR-B study.
Presenter: Carlo Cattrini
Session: Poster Display session 3
Resources:
Abstract
3301 - Implications of Single Nucleotide Polymorphisms (SNPs) in Androgen Related-Genes in Outcome of metastatic castration-resistant prostate cancer (mCRPC) patients treated with Abiraterone (Abi) and Enzalutamide (Enza)
Presenter: Isabel Aragon
Session: Poster Display session 3
Resources:
Abstract
2275 - Activating mutations in AKT1/PIK3CA are associated with poor clinical outcomes in metastatic prostate cancer (mPC)
Presenter: Simon Fu
Session: Poster Display session 3
Resources:
Abstract